AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 FEB 6 - (NewsRx.com & NewsRx.net) -- Frost & Sullivan held a conference call on January 29, 2002, to provide manufacturers, end-users and other industry participants an overview, summary, challenges, and the latest coverage on "Immunotherapies: Revolutionizing the future of Oncology."
Immunotherapies including monoclonal antibodies, angiogenesis inhibitors, cancer vaccines, antisense compounds, and gene therapy are expected to revolutionize the treatment of cancer in the near future. Existing chemotherapeutic drugs are known to induce toxicity and have various side effects, which limit the dose that is given to patients.
Most of the novel compounds in development are target specific and bind ...
Source: HighBeam Research, Frost & Sullivan Hold Analyst Briefing.(Brief Article)